Professor Chloe Orkin has worked a Consultant Physician at the Royal London Hospital for the last 16 years. She is a newly appointed Clinical Professor of HIV Medicine at Queen Mary University of London. Her clinical duties include running a busy HIV and HIV/HCV research unit. Her specialist interests are: novel anti-retroviral therapy and strategies and co-infection with viral hepatitis. She presented the first phase III trial using injectable anti-retroviral therapy. She speaks regularly at international meetings as a plenary speaker and presents primary clinical data. She has co-authored four British HIV Association guidelines on: Anti-retroviral therapy, Hepatitis, Malignancy and Routine Monitoring.
Professor Orkin led the ‘Going Viral’ blood-borne virus testing week campaign, the first of its kind, and is researching ways of implementing blood-borne virus testing.
Chloe is the current chair of the British HIV Association (BHIVA). Under her leadership BHIVA has been acknowledged as an early champion of the Undetectable=Untransmittable (U=U campaign).
As the current Athena SWAN Chair for the school of Medicine at Queen Mary University of London and the Vice President of the Medical Women’s Federation she is committed to all aspects of equality in society.
Professor Orkin's research interests lie in clinical trials in the development of novel anti-retroviral therapy and novel anti-retroviral strategies; and blood-borne virus testing.
Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavi-renz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immuno-deficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 Feb 1;68(4):535-544.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised,non-inferiority trial. Lancet HIV. 2017 Oct 5. pii: S2352-3018(17)30179-0. doi:10.1016/S2352-3018(17)30179-0.
Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 Mar 1. pii: S2352-3018(17)30031-0. doi: 10.1016/S2352-3018(17)30031-0.
Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K,Anderson J, Tong CY, Lattimore S. In-corporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. HIV Med. 2016 Mar;17(3):222-30. doi: 10.1111/hiv.12364. PubMed PMID: 26919291.
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019 Jul 12. pii: S2352-3018(19)30149-3. doi: 10.1016/S2352-3018(19)30149-3. [Epub ahead of print] PubMed PMID: 31307948.